Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.61 |
| ▸ | SRC | P12931 | 8/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.61 |
| ▸ | ABL1 | P00519 | 7/20 | 0.61 |
| ▸ | PRKDC | P78527 | 7/20 | 0.61 |
| ▸ | EGFR | P00533 | 6/20 | 0.61 |
| ▸ | HCK | P08631 | 6/20 | 0.61 |
| ▸ | KDR | P35968 | 6/20 | 0.61 |
| ▸ | MTOR | P42345 | 6/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.61 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16386491 | 1.00 | PIK3CD (0.61) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL17936598 | 1.00 | PIK3CD (0.61) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL16345696 | 0.95 | PIK3CD (0.57) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL16346192 | 0.93 | PIK3CD (0.59) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL16386556 | 0.92 | PIK3CD (0.64) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL16386553 | 0.92 | PIK3CD (0.64) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL16347594 | 0.92 | PIK3CD (0.64) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL16386555 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL16386550 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3CGSRCPIK3CAPIK3CB | |
| SCHEMBL16347380 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3CGSRCPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352359-B2 | PI3K protein kinase inhibitors | RHIZEN PHARMACEUTICALS AG (CH) | 2022-06-07 | — | — | US | claimed |
| EP-3016955-B1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS S A (CH) | 2018-03-07 | — | — | EP | claimed |
| US-20160207929-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2016-07-21 | — | — | US | claimed |
| EP-3016955-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-05-11 | — | — | EP | claimed |
| WO-2015001491-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2015-01-08 | — | — | WO | claimed |
| US-11352359-B2 | PI3K protein kinase inhibitors | RHIZEN PHARMACEUTICALS AG (CH) | 2022-06-07 | — | — | US | disclosed |
| US-11352359-B2 | PI3K protein kinase inhibitors | RHIZEN PHARMACEUTICALS AG (CH) | 2022-06-07 | — | — | US | disclosed |
| CN-111153905-A | PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors | 理森制药股份公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-105431437-B | PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors | 理森制药股份公司 | 2020-03-10 | — | — | CN | disclosed |
| EP-3016955-B1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS S A (CH) | 2018-03-07 | — | — | EP | disclosed |
| EP-3016955-B1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS S A (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20160207929-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2016-07-21 | — | — | US | disclosed |
| US-20160207929-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2016-07-21 | — | — | US | disclosed |
| US-20160207929-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2016-07-21 | — | — | US | disclosed |
| EP-3016955-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015001491-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001491-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352359-B2 | PI3K protein kinase inhibitors | PIK3CD, PIK3R5, PIK3CB | PIK3CD 1/4885PIK3CG 6/4885SRC 355/4885 |
| US-20160207929-A1 | PI3K PROTEIN KINASE INHIBITORS, PARTICULARLY DELTA AND/OR GAMMA INHIBITORS | PRKCZ, PRKCE, PRKCA | PIK3CD 4/4885PIK3CG 13/4885SRC 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.